Article Text

other Versions

PDF

EULAR evidence based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.
  1. J N Hoes (mail{at}hoesjn.org)
  1. University Medical Center Utrecht, Netherlands
    1. J WG Jacobs (j.w.g.jacobs{at}azu.nl)
    1. University Medical Center Utrecht, Netherlands
      1. M Boers (m.boers{at}vumc.nl)
      1. VU University Medical Centre, Amsterdam, Netherlands
        1. D Boumpas (boumpasd{at}med.uoc.gr)
        1. University of Crete, Greece
          1. F Buttgereit (frank.buttgereit{at}charite.de)
          1. Charité Universitätsmedizin Berlin, Germany, Germany
            1. N Caeyers (nele{at}reumanet.be)
            1. EULAR Social Leagues Patients, Belgium
              1. E H Choy (ernest.choy{at}kcl.ac.uk)
              1. King's College Hospital, United Kingdom
                1. M Cutolo (mcutolo{at}unige.it)
                1. University of Genova, Italy
                  1. J AP Da Silva (jdasilva{at}netcabo.pt)
                  1. Hospitais da Universidade de Coimbra, Portugal
                    1. G HA Esselens (greet.esselens{at}uz.kuleuven.ac.be)
                    1. University Hospital Leuven, Belgium
                      1. L Guillevin (loic.guillevin{at}cch.ap-hop-paris.fr)
                      1. Hôpitaux de Paris, université- Paris-V, France, France
                        1. I Hafström (ingiald.hafstrom{at}karolinska.se)
                        1. Karolinska Institute, Sweden
                          1. J R Kirwan (john.kirwan{at}bristol.ac.uk)
                          1. University of Bristol, United Kingdom
                            1. J Rovensky (rovensky{at}nurch.sk)
                            1. National Institute of Rheumatic Diseases Piest'any, Slovakia
                              1. A S Russell (asr{at}gpu.srv.ualberta.ca)
                              1. Clinical Member MD FRCPC, Canada
                                1. K G Saag (kenneth.saag{at}ccc.uab.edu)
                                1. University of Alabama at Birmingham, United States
                                  1. B Svensson (bjosve{at}telia.com)
                                  1. University of Lund, Sweden
                                    1. R Westhovens (rene.westhovens{at}uz.kuleuven.ac.be)
                                    1. University Hospital Leuven, Belgium
                                      1. H Zeidler (zeidler.henning{at}mh-hannover.de)
                                      1. Medizinische Hochschule Hannover, Germany
                                        1. J WJ Bijlsma (j.w.j.bijlsma{at}umcutrecht.nl)
                                        1. University Medical Center Utrecht, Netherlands

                                          Abstract

                                          Objective: To develop evidence based recommendations for the management of systemic glucocorticoid (GC) therapy in rheumatic diseases.

                                          Methods: The multidisciplinary guideline development group from 11 European countries, Canada and the USA consisted of 15 rheumatologists, 1 internist, 1 rheumatologist-epidemiologist, 1 health professional, 1 patient and 1 research fellow. The Delphi method was used to agree on 10 key propositions related to the safe use of GCs. A systematic literature search of PUBMED, EMBASE, CINAHL, and Cochrane Library was then used to identify the best available research evidence to support each of the 10 propositions. The strength of recommendation was given according to research evidence, clinical expertise and perceived patient preference.

                                          Results: The 10 propositions were generated through three Delphi rounds and included patient education, risk factors, adverse effects, concomitant therapy (i.e. non-steroidal anti-inflammatory drugs, gastroprotection and cyclo-oxygenase-2 selective inhibitors, calcium and vitamin D, bisphosphonates), and special safety advice (i.e. adrenal insufficiency, pregnancy, growth impairment).

                                          Conclusion: Ten key recommendations for the management of systemic GC-therapy were formulated using a combination of systematically retrieved research evidence and expert consensus. There are areas of importance that have little evidence (i.e. dosing and tapering strategies, timing, risk factors and monitoring for adverse effects, perioperative GC-replacement) and need further research; therefore also a research agenda was composed.

                                          • EULAR
                                          • glucocorticoids
                                          • guidelines
                                          • rheumatic diseases

                                          Statistics from Altmetric.com

                                          Request permissions

                                          If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.